

ASX ANNOUNCEMENT

KEY EUROPEAN PATENT FOR ANTI-MIDKINE ANTIBODIES GRANTED

- Patent for anti-midkine antibodies to prevent and treat cancer, inflammatory and autoimmune diseases granted in Europe
- Most important patent family in Cellmid's cancer treatment program
- Second granted patent in global patent family

SYDNEY, Tuesday, 8 October 2013: Cellmid Limited (ASX: CDY) advises that the European Patent Office has granted one of Cellmid's most important antibody patents, application EP07828015.3 (patent '15.3) entitled "Antibody recognising C-domain of midkine" (expiry 2027). The granted claims cover Cellmid's cancer program for antibodies and antibody fragments which bind to the important functional C-domain of growth factor midkine (MK). In particular, antibodies of any kind that bind to key MK C-domain epitopes are covered.

Significantly, patent '15.3 also grants composition of matter claims for MK-specific antibodies, including Cellmid's lead anti-cancer antibody. The granted claims also cover the use of any such antibody for prevention and treatment of cancer, autoimmune disease, inflammatory disease, and any disease attributed to cell migration.

In published studies, the MK C-domain has repeatedly been shown to convey most of the disease promoting activities attributed to MK. Blocking the C-domain therefore represents a powerful potential treatment option in any MK-related disease. Cellmid recently announced efficacy in cancer studies for antibodies covered in this granted European patent (*3 October 2013: Pre-clinical antibody program completed*).

"Having patents granted in Europe for our MK antibodies across such a wide array of diseases is a tremendous commercial outcome for Cellmid", said Cellmid CEO Maria Halasz. "This patent gives Cellmid very clear exclusive rights to develop MK antibodies un-encumbered by competition. Moreover, Cellmid's patent coverage for its therapeutic antibodies now extends across cancer, inflammatory and autoimmune diseases, multiple sclerosis and surgical adhesion. "

Cellmid holds the most significant intellectual property assets related to MK worldwide. Cellmid's patent portfolio currently includes 78 patents in 20 patent families, which cover use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see www.cellmid.com.au.

Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.